Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

BACKGROUND: Treatment with venetoclax + hypomethylating agents (HMAs) is standard-of-care for newly diagnosed (ND) patients with acute myeloid leukemia (AML) aged ≥75 years, or with comorbidities precluding intensive chemotherapy. We describe real-world venetoclax + HMA treatment practices and outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Vachhani, Pankit, Flahavan, Evelyn M, Xu, Tao, Ma, Esprit, Montez, Melissa, Gershon, Anda, Onishi, Maika, Jin, Huan, Ku, Grace, Flores, Brannon, Bui, Cat N, Abbas, Jonathan A, Donnellan, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Academia-Pharma Intersect
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632323/
https://www.ncbi.nlm.nih.gov/pubmed/35925602
http://dx.doi.org/10.1093/oncolo/oyac135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632323/
https://www.ncbi.nlm.nih.gov/pubmed/35925602
http://dx.doi.org/10.1093/oncolo/oyac135

Ejemplares similares